SS-31: Uses, Benefits & Research

What is SS-31?

SS-31, known generically as elamipretide (also Bendavia, MTP-131), is a synthetic tetrapeptide (D-Arg-2-methyl-2’,6’-dimethyltyrosine-Lys-Phe-NH2) with a molecular weight of 639.8 Da, designed to selectively target and restore mitochondrial function. Developed by Stealth BioTherapeutics (now acquired by Kirin), it is the most clinically advanced mitochondria-targeted peptide therapeutic.

SS-31 has an approximately 15-30 minute half-life via subcutaneous injection with about 70% bioavailability. It received FDA accelerated approval for Barth syndrome in September 2025 based on the TAZPOWER trial. For all other indications (heart failure, primary mitochondrial myopathy, aging), it remains investigational. It also has FDA Breakthrough Therapy designation for HFpEF (2019) and Fast Track designation for primary mitochondrial disease.

Important context: While SS-31 is now FDA-approved for Barth syndrome, key trials in heart failure (EMBRACE-HF) and mitochondrial myopathy (MMPOWER-3) did not meet their primary endpoints. The compound is available by prescription for Barth syndrome but not for other indications outside clinical trials.

Mechanism of Action

SS-31 works by targeting the mitochondria — specifically by binding to cardiolipin, a phospholipid found almost exclusively on the inner mitochondrial membrane:

Mechanistic Cascade

1. Cell penetration: SS-31 crosses cell membranes without a carrier and concentrates 1,000-5,000x in mitochondria
2. Cardiolipin binding: Selectively binds to cardiolipin on the inner mitochondrial membrane
3. Cardiolipin protection: Prevents cardiolipin peroxidation by reactive oxygen species
4. Cristae stabilization: Maintains normal mitochondrial cristae architecture
5. Supercomplex stabilization: Stabilizes electron transport chain supercomplexes (Complex I-III-IV assemblies)
6. Improved electron flow: Reduces electron leak and improves coupling of oxidative phosphorylation
7. Reduced ROS: Decreases superoxide production by 40-60%
8. Increased ATP: Net result is restored ATP production capacity

Molecular Targets

Target	Evidence	Effect
Cardiolipin	Direct binding demonstrated	Stabilizes inner membrane; protects cristae
ETC Complexes I-IV	Inferred from functional data	Improves efficiency; reduces electron leak
ROS production	Direct measurement	40-60% reduction in superoxide
Mitochondrial membrane potential	Direct measurement	Restores membrane potential in damaged mitochondria

This mechanism is particularly relevant in conditions where mitochondrial dysfunction drives disease pathology — heart failure, primary mitochondrial diseases, muscular dystrophies, and age-related cellular decline.

Clinical Evidence

Landmark Trials

Trial	Phase	N	Population	Key Result
EMBRACE-HF	II	67	HFpEF	Primary endpoint (KCCQ) NOT MET. Secondary: +42m 6MWD vs +10m placebo (PMID: 32068002)
PROHIBIT	II	185	HFrEF	Well tolerated; improved mitochondrial markers
MMPOWER-3	II/III	218	Primary mitochondrial myopathy	Primary endpoint NOT MET. Post-hoc genotype-specific benefit (PMID: 37268435)
TAZPOWER	II	12	Barth syndrome	168-week safety/efficacy maintained (PMID: 38602181)
SPIRE-1	II	250	HFpEF	+1.8 vs +0.7 mL/kg/min peak VO2
DMD study	II	~50	Duchenne MD	Modest functional improvement

Evidence Base

• Phase 2 trials completed: 8+
• Phase 3 trials active: 2 (SPRING-HF, n=600; mitochondrial disease, n=400)
• Total subjects exposed: 800-1,000
• Placebo-controlled RCTs: 6+

Key Limitation

Critical limitation: EMBRACE-HF did not meet its primary endpoint (KCCQ quality-of-life score). The 6-minute walk distance improvement was a secondary endpoint only. MMPOWER-3 also failed its primary endpoint, though post-hoc analysis showed genotype-specific benefit. The Barth syndrome indication (TAZPOWER) has the strongest evidence. The biomarker-to-clinical-outcomes gap — clear mitochondrial function improvement but variable functional endpoints — is the central question that Phase 3 trials must resolve.

Active Trials (as of March 2026)

Trial	Phase	Status	N	Focus
SPRING-HF (NCT05065528)	III	Recruiting	600	HFpEF
NCT05432142	III	Recruiting	400	Primary mitochondrial disease

Drug Interactions & Contraindications

SS-31 has a favorable drug interaction profile:

• Not metabolized by CYP450 — peptide cleared by proteolysis, minimizing hepatic drug interactions
• No known interactions from clinical trial data — can be combined with standard heart failure medications (ACEi, ARBs, beta-blockers, diuretics)
• Statins: No interaction expected based on clean co-administration data in trials
• Antioxidants: Theoretical additive/synergistic effect — no human interaction data

No formal contraindications have been identified in clinical trials. Pregnancy is avoided as the compound has not been studied in pregnant women.

Safety & Side Effects

SS-31 has demonstrated an excellent tolerability profile across all Phase 2 trials, with adverse event rates very close to placebo:

Adverse Event	SS-31	Placebo	Difference
Injection site reactions	8-12%	5-8%	Minimal
Headache	10-15%	8-12%	Minimal
Nausea	6-10%	5-8%	Minimal
Dizziness	5-8%	4-6%	Minimal

Key safety findings:

• No serious adverse events attributed to SS-31 in any Phase 2 trial
• Cardiac SAEs in heart failure populations occurred at rates consistent with underlying disease, not drug effect
• No treatment discontinuations exceeding placebo
• No effect on vital signs or ECG parameters
• 168-week open-label extension in Barth syndrome showed maintained safety (PMID: 38602181)

Long-term safety data beyond 168 weeks (Barth syndrome) and 1 year (other indications) is still accumulating.

Honest Bottom Line

SS-31 (elamipretide) received FDA approval for Barth syndrome in September 2025, validating its mitochondrial mechanism. However, results in other indications have been mixed: EMBRACE-HF (heart failure) and MMPOWER-3 (mitochondrial myopathy) both failed their primary endpoints. The 42-meter 6-minute walk distance improvement in EMBRACE-HF was a secondary endpoint — not the primary measure of efficacy.

The safety profile is favorable, with adverse event rates close to placebo. For Barth syndrome, elamipretide is available by prescription. For heart failure and other mitochondrial conditions, it remains investigational — the Phase 3 SPRING-HF trial readout will be decisive. Patients should understand the distinction between the approved Barth syndrome indication and the unproven heart failure/myopathy indications.